The tweet was deleted by the author.
But we saved everything 🙂.
Biotechnology firm Immuneering reflects on its achievements throughout 2025 as it makes strides toward its mission of extending the lives of cancer patients beyond their disease. The company attributes this progress to the dedication of its team, the support of investigators and investors, and the inspiration drawn from patients themselves. Looking forward to 2026, Immuneering is committed to building upon this momentum to further advance their initiatives, aiming for even greater impact in the oncology field. The emphasis for the coming year remains on innovation and collaboration to improve treatment outcomes for cancer patients worldwide.
Immuneering’s ongoing focus on innovation and collaborative research aligns with earlier advances detailed during its promising pancreatic cancer treatment trials. These efforts are further underscored by strategic developments announced at the JPMorgan Healthcare Conference, where the company outlined its Phase 3 development plans for atebimetinib—key milestones shaping Immuneering’s path as it prepares for the year ahead.